Go to:
Logótipo
Comuta visibilidade da coluna esquerda
Você está em: Start > Publications > View > Rivastigmine for the treatment of Parkinson's disease dementia [Rivastigmina no tratamento da demência da doença de Parkinson]
Publication

Publications

Rivastigmine for the treatment of Parkinson's disease dementia [Rivastigmina no tratamento da demência da doença de Parkinson]

Title
Rivastigmine for the treatment of Parkinson's disease dementia [Rivastigmina no tratamento da demência da doença de Parkinson]
Type
Another Publication in an International Scientific Journal
Year
2014
Journal
Title: SinapseImported from Authenticus Search for Journal Publications
Vol. 14
Pages: 21-25
ISSN: 1645-281X
Indexing
Publicação em Scopus Scopus - 0 Citations
Other information
Authenticus ID: P-00M-8DB
Abstract (EN): Introduction: There is a high prevalence of dementia in Parkinson's disease, which is cumulative along disease course. Parkinson's disease dementia (PDD) causes additional significant disability, with loss of independence and troublesome behavioral disorders. Aim: Review and synthesis of published scientific data regarding the clinical results of rivastigmine in PDD. Results: The EXPRESS trial was published in 2004; this was randomized, controlled, doubleblind trial that demonstrated the efficacy of rivastigmine capsules (up to 12 mg/day) in PDD, concerning cognition, behavioral and activities of daily living. The open label extension phase of this trial showed clinical long term benefits of rivastigmine in PDD. Most adverse events associated with rivastigmine were cholinergic, and caused interruption of therapy in some cases. The IDEAL trial, a randomized, double blind, double dummy trial enrolling Alzheimer's disease patients only, demonstrated that the rivastigmine transdermal patch and the capsules were equally effective at the higher dosages. Tolerability was similar to patch and placebo, and much better than to capsules. A recently published randomized open label study compared the long-term safety of rivastigmine capsules (12 mg/day) and patch (9.5 mg/24h) in PDD, showing that safety was similar for both formulations, but a higher incidence of cholinergic adverse events was seen with capsules, and skin erythema was noticed in a small portion of patients treated with the transdermal patch. Conclusion: Available scientific data suggest that rivastigmine is an effective and safe drug for the treatment of PDD. Literature supports the clinical usefulness of both capsules (up to 12 mg/day) and transdermal patch (9.5 mg/24h), with additional benefits with the latter concerning tolerability, with the exception of erythema, which leads to treatment discontinuation in a small portion of cases. Rivastigmine is a leading drug in the treatment of PDD, and transdermal patch is a clinically valuable option.
Language: English
Type (Professor's evaluation): Scientific
Documents
We could not find any documents associated to the publication.
Related Publications

Of the same authors

Writeclick: Neuropsychological outcome after deep brain stimulation for Parkinson disease (2016)
Another Publication in an International Scientific Journal
João Massano; Bronstein, JM
Wolfram syndrome: Phenotypic heterogeneity and novel genetic variants in the WFS1 gene (2022)
Another Publication in an International Scientific Journal
Ferreira, JL; Carvalho, V; Espada, F; João Massano; Marques, AP; Principe, RM
Think tank: Strategic report on the scientific biomedical publication in Portugal [Think tank: Relatório estratégico sobre publicação científca biomédica em portugal] (2014)
Another Publication in an International Scientific Journal
Marinho, RT; Donato, H; Fernandez Llimos, F; João Massano; Silva, JM; Almeida, M; Carona Carvalho, J; Villanueva, T; Fonseca, JE
Think Tank: Strategic Report on the Scientific Biomedical Publication in Portugal (2014)
Another Publication in an International Scientific Journal
Marinho, RT; Donato, H; Fernandez Llimos, F; João Massano; Silva, JM; Almeida, M; Carona Carvalho, J; Villanueva, T; Fonseca, JE

See all (104)

Recommend this page Top
Copyright 1996-2025 © Faculdade de Direito da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z
Page created on: 2025-08-06 at 16:23:17 | Privacy Policy | Personal Data Protection Policy | Whistleblowing